LCTX
ANALYST COVERAGE5 analysts
BUY
Buy
5100%
5 Buy (100%)0 Hold (0%)0 Sell (0%)
Full report →
Key MetricsTTM
Market Cap$299.16M
Revenue TTM$14.78M
Net Income TTM-$64.21M
Free Cash Flow-$22.30M
Gross Margin98.0%
Operating Margin-255.1%
Net Margin-434.4%
Return on Equity-152.1%
Return on Assets-58.6%
Debt / Equity0.04
Current Ratio6.89
EPS TTM$-0.26
PRICE
Prev Close
1.24
Open
1.22
Day Range1.20 – 1.27
1.20
1.27
52W Range0.48 – 2.09
0.48
2.09
45% of range
VOLUME & SIZE
Avg Volume
1.2M
FUNDAMENTALS
P/E Ratio
-4.1x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
0.98
Market-like
TECHNICAL
RSI (14)
38
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 21
DEx-Dividend
In 90 days
Aug 18
PDividend Pay
In 104 days
Sep 1

LCTX News

About

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Brian Culley
Charlotte HubbertVice President of Corporate Strategy & Development
Priyantha HerathSenior VP & Head of Clinical Operations
Brian CulleyChief Executive Officer, President & Director
Alexandra HernandezSenior Director of Finance & Controller
Brandi L. RobertsConsultant
Jill Ann HoweChief Financial Officer
Harold D. WaitzVice President of Regulatory Affairs & Quality Control
Rami SkaliterChief Executive Officer of Cell Cure Neurosciences
George A. SamuelGeneral Counsel & Company Secretary
Ioana C. HoneDirector of Investor Relations